The research, conducted at Hospital Canselor Tuanku Muhriz of Universiti Kebangsaan Malaysia and published in BMC Cancer, examined 241 women with clinically node-negative early breast cancer, all staged cT1–2N0M0, who underwent sentinel lymph node biopsy between January 2018 and December 2025. The team, led by surgeon Hadija Mustamin together with pathologists and community health researchers, asked a deceptively simple question: does the density of tumour-infiltrating lymphocytes, or TILs, in the tumour stroma correlate with whether cancer cells are found in the sentinel node?

The findings were striking. Among the cohort, 67 patients — 27.8 percent — had metastasis to the sentinel lymph node. But the distribution of that risk was far from even. When pathologists graded stromal TIL levels according to the internationally accepted 2014 guidelines of the International TILs Working Group, they found that two-thirds of the patients fell into the low-TIL category, 17.4 percent into the intermediate category, and 16.6 percent into the high category. Critically, the highest proportion of nodal metastasis occurred in the group with the fewest infiltrating lymphocytes, a statistically significant association with a p value of 0.023.

To understand why this matters, one must appreciate what TILs actually represent. Tumour-infiltrating lymphocytes are immune cells — predominantly T cells — that have migrated from the bloodstream into the tumour microenvironment, a biological indication that the host immune system has recognised the malignancy and mounted a response. In recent years, TIL assessment has graduated from a curiosity of tumour immunology to a practical, reproducible pathology metric. In triple-negative and HER2-positive breast cancers, high TIL counts are already associated with better responses to neoadjuvant chemotherapy and improved survival. What this new study adds is a potential role in the preoperative and perioperative decision-making around the axilla.

The statistical backbone of the study was a two-stage logistic regression strategy. The researchers first screened clinicopathological variables — tumour size, histological type, grade, lymphovascular invasion, hormone receptor status and TIL category — using univariable analyses, and then entered any variable with a p value below 0.25 into a multivariable model. After adjustment, two factors emerged as independent predictors of sentinel node involvement. Higher TIL levels were associated with lower odds of metastasis, with an adjusted odds ratio of 0.977 per unit increase (95 percent confidence interval 0.961–0.994; p = 0.007). Lymphovascular invasion, the histological evidence of tumour cells invading blood or lymphatic vessels, was independently associated with nodal spread, carrying an adjusted odds ratio of 0.290 (95 percent CI 0.156–0.537; p < 0.001), meaning its presence substantially raised the odds of metastasis.

Interestingly, tumour size — long regarded as a cornerstone of nodal risk prediction — was associated with sentinel lymph node metastasis in the univariable analysis but lost its significance once other factors were accounted for. That statistical humility is itself informative: it suggests that within this cohort of small, clinically node-negative tumours, the biology of the tumour microenvironment and the presence of lymphovascular invasion may carry more predictive weight than size alone. If validated, such a shift could change how pathologists’ reports are weighted in surgical planning.

The clinical implications are potentially significant. Sentinel lymph node biopsy, while far less morbid than full axillary dissection, still carries risks of lymphoedema, seroma, nerve injury and infection. A reliable, cheap, microscope-based biomarker that stratifies nodal risk before surgery could, in principle, help identify patients in whom biopsy yields the greatest information, or in the longer term, support more selective approaches to axillary staging. Because TIL scoring requires only routine haematoxylin and eosin slides and a trained pathologist, it is vastly more accessible than genomic assays or advanced imaging, an especially important consideration in resource-constrained health systems such as much of Southeast Asia.

The authors are careful, and appropriately so, about the limits of their work. This was a single-centre, cross-sectional study, which captures association but cannot establish that low TIL levels cause nodal spread. Only a single pathologist scored the slides, raising questions about inter-observer reproducibility that multi-reader studies would need to resolve. The cohort spans tumours of all molecular subtypes, and TIL biology differs markedly between triple-negative, HER2-positive and luminal cancers; subtype-specific analyses in larger, prospective cohorts with external validation will be required before TIL assessment can be folded into clinically useful prediction models for nodal status. The study received no external funding, and the analysis reflects institutional records from one Malaysian tertiary centre.

Nevertheless, the study joins a rapidly expanding body of evidence that the immune microenvironment is not merely a bystander in cancer progression but an active determinant of how tumours behave. A tumour bristling with lymphocytes appears, in this data, to be a tumour less likely to have seeded the regional nodes — a biological narrative that makes intuitive sense, since a robust local immune response may constrain the earliest steps of dissemination. Conversely, an immunologically cold tumour, walled off from immune attack, may enjoy freer rein to invade lymphatic channels and establish footholds downstream.

For patients, the message is not one of immediate change in care — no guideline today spares anyone a sentinel node biopsy on the basis of TIL counts. But it is another step toward a future in which the pathology report of a breast cancer describes not just what the tumour is, but what the body is doing about it. As immunotherapy reshapes oncology and immune biomarkers move from research benches to clinical reports, studies like this one map the terrain where tumour immunology and surgical decision-making converge. Whether the quiet presence of lymphocytes in a tumour’s stroma can one day spare a woman an unnecessary procedure remains to be proven, but this Malaysian cohort offers a compelling early signal that the immune system has been keeping records all along — records pathologists are only now learning to read.

Subject of Research: Association between stromal tumour-infiltrating lymphocyte levels and sentinel lymph node metastasis in early breast cancer

Article Title: Tumour-infiltrating lymphocytes are associated with sentinel lymph node metastasis in early breast cancer: a cross-sectional study

Article References: Tumour-infiltrating lymphocytes are associated with sentinel lymph node metastasis in early breast cancer: a cross-sectional study. (n.d.). https://doi.org/10.1186/s12885-026-17012-z

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17012-z

Keywords: breast cancer, tumour-infiltrating lymphocytes, sentinel lymph node metastasis, tumour immune microenvironment, lymphovascular invasion, sentinel lymph node biopsy, cancer metastasis, tumour immunology, early breast cancer, pathology biomarker, logistic regression, BMC Cancer

The metastatic cascade begins when cancer cells detach from the primary tumour mass, enter systemic circulation, and seed distant organs. At this nascent stage, worryingly few DTCs survive immune clearance despite the robust presence of cytotoxic T cells and NK cells which are specialized in identifying and eliminating aberrant cells. The researchers addressed this fundamental gap by employing a sophisticated model of triple-negative breast cancer expressing a visible antigen paired with cognate CD8+ T cells, allowing real-time tracking and functional interrogation of DTCs as they colonize secondary sites. This approach enabled the characterization of molecular signatures associated with immune evasion specifically at the metastatic seeding stage.

Central to their discovery was the activation of the glucocorticoid receptor (GR) within surviving DTCs. GR, a transcription factor well-known for orchestrating cellular responses to stress hormones such as cortisol, was found to be a pivotal regulator of immune resistance. Upon GR activation, DTCs effectively dampened the expression of molecules critical for recognition and destruction by cytotoxic T cells and NK cells. This newfound axis between glucocorticoid signaling and immune evasion reveals an unexpected layer of complexity in tumour–immune interactions that appears uniquely operational during early metastatic dissemination.

The researchers harnessed an innovative niche-labeling platform to profile the local microenvironment of DTCs dynamically. This system led to the identification of the FAS–FASL pathway as a key cytotoxic mechanism deployed by immune cells to target and eliminate disseminated tumour cells. FAS ligand (FASL) expressed on immune cells binds to FAS receptors on tumour cells, triggering apoptotic cell death. However, intriguingly, the activation of GR resulted in downregulation of FAS within DTCs. This suppression of the FAS–FASL death axis provided a mechanistic explanation for how DTCs subvert immune-mediated clearance, achieving persistence despite an intact immune system.

By integrating pharmacological inhibition of the glucocorticoid receptor alongside immunotherapy in murine models, the study demonstrated significant therapeutic potential. Combined treatment regimes reduced metastatic burden substantially and extended survival times. Such findings support the notion that therapies targeting GR signaling could be decisive adjuncts to existing immunotherapies, particularly by eradicating residual disseminated tumour cells before they evolve into overt, clinically detectable metastases. This strategy could revolutionize the management of metastatic disease by intervening at the critical juncture of initial seeding.

Beyond triple-negative breast cancer, which notoriously evades many conventional treatment approaches, the implications of these findings are far-reaching. The immune evasion mechanisms elucidated here may operate across a wide range of solid malignancies, presenting new universal targets for drug development. The exquisite sensitivity of DTCs to immune cytotoxicity, and their simultaneous capacity to activate these protective GR-dependent pathways, underscore the dynamic tug-of-war governing metastatic success or failure.

This research also highlights the distinct phenotypic and functional heterogeneity of tumour cells during the metastatic trajectory. It challenges the conventional wisdom of treating metastatic disease as a mere extension of the primary tumour’s biology. Instead, it advocates for dedicated therapeutic strategies tailored specifically to the seeding and survival phase of metastasis—a window of opportunity that has been largely neglected until now. Precision targeting of GR activity in DTCs offers a novel approach to intercept the cancer before it becomes clinically unmanageable.

The study’s innovative use of an antigen–T cell cognate system represents a significant technical advance, enabling unprecedented resolution of cancer–immune dynamics in vivo. This model not only reinforces the pivotal role of CD8+ T cells in mediating anti-metastatic immunity but also clarifies how immune pressures sculpt tumour evolution at microanatomic levels. Elucidating factors like GR that modulate these interactions provides therapeutic nodes to sensitize DTCs to host defenses.

Furthermore, the identification and functional validation of the FAS–FASL pathway in this context offer a critical insight into cytotoxic immune mechanisms that can be harnessed for enhanced cancer elimination. While FAS-mediated apoptosis is a well-characterized immune defense pathway, its selective repression by GR within DTCs reveals a previously unappreciated strategy of immune escape. This finding revitalizes interest in modulating death receptor pathways as adjuncts to immune checkpoint blockade.

Looking forward, the translation of GR inhibitors into clinical regimens demands careful consideration given glucocorticoids’ broad physiological roles. Nonetheless, the selective vulnerability of DTCs to GR inhibition, when combined with immunotherapy, provides a compelling rationale for clinical trials aimed at testing this strategy. Optimizing dosing and timing to maximize anti-metastatic effects without disrupting systemic homeostasis will be key challenges ahead.

In summary, this seminal study unravels a critical glucocorticoid–FAS axis that governs immune evasion during metastatic seeding. By disarming the immune cell-mediated cytotoxic attack at this pivotal stage, DTCs gain a foothold for subsequent metastatic outgrowth and disease progression. This discovery not only advances the fundamental understanding of cancer biology but also opens new therapeutic avenues to intercept metastasis proactively. Targeting the molecular interplay that allows disseminated tumour cells to slip past immune surveillance could change the landscape of cancer treatment and improve survival for countless patients.

This work exemplifies the power of combining state-of-the-art experimental models with precision molecular analyses to decode the complexities of tumour-host interactions. Their revelations about the dynamic immune evasion tactics employed by DTCs underscore the necessity of early, aggressive interventions tailored to the metastatic microenvironment. As immunotherapies continue to reshape oncology, integrating mechanistic insights such as the glucocorticoid receptor’s role promises more durable and effective treatments.

Ultimately, dismantling the immune privilege acquired by disseminated tumour cells could tip the balance back in favor of the host immune system, converting metastasis from a lethal endpoint into a manageable condition. The identification of GR as a driver of this immune escape not only enriches the scientific narrative surrounding metastasis but also charts a future direction for cancer therapeutics focused on eliminating minimal residual disease and preventing lethal tumour dissemination.

Subject of Research: Mechanisms of immune evasion by disseminated tumour cells during early metastatic seeding in triple-negative breast cancer.

Article Title: A glucocorticoid–FAS axis controls immune evasion during metastatic seeding.

Article References:
Cassandras, M., Sanchez, X., Hsu, L. et al. A glucocorticoid–FAS axis controls immune evasion during metastatic seeding. Nature (2026). https://doi.org/10.1038/s41586-026-10222-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10222-2